Every 8-K that ENVUE MEDICAL INC NEW (FEED) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow FEED and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full FEED filings page.
ENvue Medical, Inc. entered into a secured financing agreement with Alpha Capital Anstalt, which agreed to provide up to $1,000,000 in aggregate principal through tranches agreed by the parties. The lender funded an initial $250,000 tranche on October 8, 2026. Amounts outstanding accrue interest at 10% per annum; following and during an Event of Default, the rate increases to the lesser of 18% per annum or the highest rate permitted by applicable law. Principal and accrued interest are due December 31, 2026, although the lender may extend maturity in three-month increments through December 31, 2028. The obligations are secured by a continuing security interest in substantially all company assets, including accounts, inventory, certain deposits, intellectual property and subsidiary equity.
Separately, holders of at least 70% of the outstanding Series X Non-Voting Convertible Preferred Stock agreed to amend its terms. The amendment sets the conversion price at $0.50 per share, subject to adjustment, and revises provisions governing subsequent equity sales, including conversion-price adjustments for certain dilutive issuances. ENvue Medical filed the Certificate of Amendment with the Delaware Secretary of State on October 12, 2026.
ENvue Medical, Inc. (FEED) is implementing a reverse stock split of its common stock at a 1-for-12 ratio, effective at 12:01 a.m. Eastern Time on September 1, 2026. The split was approved by the board under authority granted by stockholders at a special meeting on August 14, 2026 and effected through a Certificate of Amendment filed in Delaware on August 28, 2026.
Following the reverse split, the number of outstanding common shares will be reduced from 11,084,616 to approximately 923,718, while the authorized common shares remain at 40,000,000. No fractional shares will be issued; instead, positions will be rounded up to the nearest whole share. The stock will continue trading on the Nasdaq Capital Market under the symbol FEED with a new CUSIP 63008J876, and options, warrants, convertible securities and restricted stock will be proportionally adjusted so that ownership percentages and voting power remain substantially unchanged.
ENvue Medical, Inc. held a special meeting of stockholders on August 14, 2026. Stockholders approved an amendment to the Amended and Restated Certificate of Incorporation authorizing the Board of Directors, in its discretion and prior to the one-year anniversary of the meeting, to implement a reverse stock split of the common stock at a ratio between 1-for-2 and 1-for-50, with the exact ratio to be set and publicly announced by the Board. The reverse split proposal received 3,847,974 votes for, 1,062,981 against, and 19,288 abstentions. Stockholders also approved an adjournment proposal by 4,199,681 votes for, 594,319 against, and 136,243 abstentions, although no adjournment was ultimately made.
ENVUE Medical, Inc. entered into a new committed equity facility of up to $50.0 million with an institutional investor under a Common Shares Purchase Agreement. The company may, at its discretion, direct the investor to buy common shares over a period extending to the first day of the month following 36 months after Commencement, once resale registration for these shares is effective.
Shares sold under the agreement will be priced at 90% of the lowest volume weighted average price over the three trading days preceding each purchase date. The company must apply 40% of net proceeds to redeem outstanding Series X Preferred Stock until fully redeemed, with the balance for working capital and general corporate purposes.
Separately, a Second Amendment to the Series H Purchase Agreement increases Additional Investment Rights to $59,000,000 Stated Value (59,000 Series H Preferred shares and $53,100,000 Subscription Amount), subject to shareholder approval. The investor also agreed to exercise at least $10.0 million of these rights within twelve months after shareholder approval, with a monthly minimum of $833,333.33, adjusted downward upon specified fund-raising events.
ENvue Medical, Inc. reported that on July 14, 2026, directors David Johnson and Nino Pionati voluntarily resigned from the Board of Directors. The company states their resignations were not due to any disagreement regarding its operations, policies or practices.
The remaining directors appointed Zvi Joseph and Lior Buchman to fill the vacancies. Joseph joined the Audit Committee and the Nominating and Corporate Governance Committee. Buchman joined the Audit Committee and the Compensation Committee and became Compensation Committee Chair. Existing director Zeev Rotstein, M.D. was appointed Chair of the Nominating and Corporate Governance Committee and Chairman of the Board. Joseph and Buchman will receive the same fees as other non‑executive directors, and the company notes there are no special arrangements or related‑party transactions requiring disclosure.
ENvue Medical, Inc. received a Nasdaq Staff Determination Letter on July 10, 2026 stating that its common stock has failed to meet the Nasdaq Capital Market minimum bid price requirement. The closing bid price was below $1.00 per share for 30 consecutive business days from May 26, 2026 through July 8, 2026, violating Nasdaq Listing Rule 5550(a)(2).
Ordinarily the company would receive a 180-calendar day grace period, but under Nasdaq Listing Rule 5810(c)(3)(A)(iv) it is not eligible for any compliance period because it effected a 1-for-10 reverse stock split on August 12, 2025. ENvue Medical plans to request a hearing before a Nasdaq Hearings Panel under the Nasdaq Listing Rule 5800 Series, which will stay any suspension or delisting action while the appeal is pending. The company notes there is no assurance the Panel will grant continued listing or that it will regain and maintain compliance with the Minimum Bid Price Requirement and other Nasdaq standards.
ENvue Medical, Inc. reported changes to leadership compensation and governance. A subsidiary signed a first amendment to the employment agreement with CEO Doron Besser, M.D., confirming an initial grant of 180,000 restricted stock units, equal to 9% of the company’s fully diluted common stock as of his agreement’s effective date.
The amendment also provides quarterly restricted stock unit “gross-up” grants, subject to board approval, to keep Dr. Besser at a 9% equity interest, including a prorated grant if he is terminated without Cause or resigns for Good Reason. Separately, ENvue entered a chairman agreement with David Johnson, who will chair the board as an independent contractor, receive a flat $10,000 monthly fee, and be granted restricted stock units representing 3.5% of fully diluted common stock, plus potential anti-dilution true-up grants for up to two years.
ENvue Medical, Inc. entered into an Amendment Agreement with required holders of its Series H Convertible Preferred Stock. The parties agreed to amend the existing Certificate of Designations by filing a Certificate of Amendment that removes the defined Floor Price applicable to the Series H preferred.
In return, holders of the Preferred Stock agreed to exercise $2,500,000 of the Additional Investment Right described in the July 18, 2025 Securities Purchase Agreement. The Certificate of Amendment was filed with the Delaware Secretary of State on January 30, 2026 and became effective upon filing, modifying the rights and preferences of the Series H preferred shares.